✦ LIBER ✦

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Scribed by Dan T. Vogl; Edward A. Stadtmauer; Paul G. Richardson; Pieter Sonneveld; Michael W. Schuster; David Irwin; Thierry Facon; Jean-Luc Harousseau; Anthony Boral; Rachel Neuwirth; Kenneth C. Anderson

Book ID: 108676478
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 108 KB
Volume: 147
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07875.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

The efficacy and safety of bortezomib an

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

✍ Giulia Benevolo; Alessandra Larocca; Massimo Gentile; Patrizia Pregno; Francesca 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

High response rate to bortezomib with or

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

✍ Joseph R. Mikhael; Andrew R. Belch; H. Miles Prince; Maria Nambo Lucio; Angelo M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

Safety and efficacy of a combination the

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience

✍ Tommaso Caravita; Agostina Siniscalchi; Andrea Tendas; Luca Cupelli; Micaela Ale 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 60 KB